Major Depressive Disorder

New research brings us closer to learning about the associations between psychological states, quality of life, and cardiovascular health.

Findings from a new study may have implications in relation to early childhood interventions and later targeted pharmacotherapies for MDD.

This special collection provides new insights on major aspects of depression: psychopharmacology, therapeutic interventions, major depressive episodes, biomarkers, and pseudobulbar affect.

Do personality disorders get a bad rap? Take the quiz and learn more.

The authors discuss two fundamental misconceptions: the myth of the patient’s autonomy, and the myth of the incurability of the patient’s illness.

In considering how best to disseminate the many psychotherapeutic techniques to practicing clinicians, the author reviews findings and changes to guidelines on depression treatments.

The use of biomarkers to assist with optimizing treatment decisions for depression has been receiving increasing attention. Here is an overview of the challenges and barriers that must be overcome before therapeutic markers can effectively be utilized in practice.

ECT is a highly effective treatment for depression, but a portion of patients fail to respond as hoped. Clinical variables have overall limited utility as a predictor of response. Is inflammation the key?

Highlights of 3 new studies investigate how to choose the best therapy for depression as well as the negative influences of polypharmacy and social media.

Researchers accumulated information on self-reported emotion regulation in patients with current and remitted MDD. Then, they crunched the data.

The immune-brain loop: a world where more and more clinicians boldly go-and thrive-among new discoveries.

More than any other medical specialty, we sometimes feel compelled, and empowered, to treat patients against their will. With this comes two great responsibilities.

The thorny issue of “end-of-life care” is likely to remain controversial in the US, with physicians themselves holding a wide variety of views.

This month's roundup features noteworthy stories from around the web: the humanitarian crisis at the border, new gaming disorder diagnosis, a medication investigation of over 26,000 adult patients, a boundary-busting neurologist, and physician and celebrity suicides.

For the first time, a study has shown comprehensive evidence for the effect of depression on decline in overall cognitive function. Plus, 2 more findings.

In the final part of our discussion with Janae Sharp, Janae further discusses the loss of her physician husband to suicide and how best to support others through grief.

Researchers may have cracked the code to the mystery of depression, inflammation, and C-reactive protein.

The first clinical trial of probiotics in bipolar disorder is out, and the results look promising.

Because immunologic processes connected to psychiatric disorders have received considerable attention, we invite you to test your knowledge on the pathophysiologic process of depression and inflammation.

How do brain changes, inflammation, and genetic risk factors modulate the development of PTSD or depression in patients with a history of trauma?

Immunologic processes may play a pivotal role in the development and maintenance of psychiatric disorders, opening an entire new avenue for novel strategies to prevent and treat psychiatric disease.

Charles Nemeroff, MD, PhD argues for psychiatrists to consider obtaining inflammatory marker labs on every patient that they see.

In addition to psychosocial problems, there is a growing realization that PTSD may also lead to or exacerbate chronic medical health conditions.

This 2-part Special Report devotes itself to the new inflammatory world that clinicians and researchers find themselves in. Most of our prior and current preconceptions about the role of immunity and mental illness have been-and are-wrong.

Relapse in MDD is associated with morphologic brain changes; stopping exercise may increase depressive symptoms; and inflammatory biomarkers may predict which treatment-resistant MDD patients benefit from ECT.